# US 2023/0256011 A1 · Chlorite In the Treatment of Acute Respiratory Distress Syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0256011 A1
- Document ID: US20230256011A1
- Status: Published application
- Kind: A1
- Application number: 18/002,385
- Filed: 2021-06-24
- Published: 2023-08-17
- Earliest claimed: 2020-06-30
- Applicants: The Regents of the University of California
- Inventors: Michael S. McGrath
- Web page: https://patentgrep.com/patent/US20230256011A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- C01B 11/10: Chlorites
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of treating a subject having, or at risk of developing, acute respiratory distress syndrome (ARDS) by administering a chlorite composition in an amount effective to treat the subject. Aspects of the methods also include administering a chlorite formulation to a subject having or suspected of having a coronavirus infection, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Also disclosed herein are methods of regulating macrophage activity in a subject having, or at risk of developing ARDS by contacting a macrophage of a subject having or at risk of developing ARDS with a chlorite composition in an amount effective to regulate one or more functional properties of the macrophage. The disclosure also features methods of determining inhibition of a ARDS-induced macrophage activity by a chlorite agent.

## Claims

### Claim 1

A method of treating a subject having or at risk of developing acute respiratory distress syndrome (ARDS), the method comprising:
administering a chlorite composition to a subject having or at risk of developing ARDS, wherein the chlorite composition is administered in an amount effective to treat the subject.

### Claim 2 (depends on 1)

The method of any one of claim 1, wherein chlorite is in the form of a pharmaceutically acceptable chlorite salt.

### Claim 3 (depends on 3)

The method of claim 3, wherein the chlorite salt is sodium chlorite.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the chlorite composition is administered intravenously.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the chlorite is administered at a dose of from about 1 to 5 mg/kg of chlorite per day.

### Claim 6 (depends on 5)

The method of claim 5, wherein the chlorite is administered to the subject for at least a 1 hour period.

### Claim 7 (depends on 5, 6)

The method of claim 5 or 6, wherein the chlorite is administered every day for one week or more.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the subject has or is suspected of having a coronavirus infection.

### Claim 9 (depends on 8)

The method of claim 8, wherein the coronavirus is SARS-CoV, MERS-CoV, or SARS-CoV-2.

### Claim 10 (depends on 9)

The method of claim 9, wherein the coronavirus is SARS-CoV-2.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the subject has or is suspected of having COVID-19.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the chlorite composition comprises a purified sodium chlorite, wherein the purified sodium chlorite is at least 98% pure.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition is a liquid further comprising a pH adjusting agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pH adjusting agent is a phosphate buffer.

### Claim 15

A method of treating a subject having or suspected of having a coronavirus infection, the method comprising:
administering a chlorite composition to a subject having or suspected of having a coronavirus infection, wherein the chlorite composition is administered in an amount effective to treat the subj ect.

### Claim 16 (depends on 15)

The method of claim 15, wherein the coronavirus is HCoV-299E, HCoV-OC43, SARS-CoV, HCoV-NL63, HKU1, MERS-CoV, or SARS-CoV-2.

### Claim 17 (depends on 16)

The method of claim 16, wherein the coronavirus is SARS-CoV-2.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15 to 17, wherein the subject has or is at risk of developing acute respiratory distress syndrome (ARDS).

### Claim 19

A method of regulating macrophage activity in a subject having or at risk of developing an acute respiratory distress syndrome (ARDS), comprising:
contacting a macrophage of a subject having or at risk of developing an acute respiratory distress syndrome (ARDS), with a composition comprising an amount of a chlorite composition effective to regulate one or more functional properties of the macrophage.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or more functional properties comprises one or more of macrophage activation, a thrombotic process, a complement activation process, microbial translocation, a non-phagocytic phenotype, an inflammatory factor, and a monocytic migration process into a diseased tissue.

### Claim 21 (depends on 20)

The method of claim 20, wherein the functional property is inappropriate macrophage activation, and the contacting results in the regulation of the macrophage activation.

### Claim 22 (depends on 20)

The method of claim 20, wherein the functional property is an inflammatory factor, and the contacting decreases the level of the inflammatory factor activity as measured in the blood.

### Claim 23 (depends on 22)

The method of claim 22, wherein the inflammatory factor is interleukin-18 (IL-18), C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), interleukin-1 receptor antagonist (IL1Ra), osteopontin (OPN), or a combination thereof.

### Claim at position 24 (depends on 19)

23a. The method of claim 19, wherein the functional property is a soluble plasma factor associated with one or more of cellular activation, inflammation, and infiltration of bacteria, and the contacting decreases the level of the soluble plasma factor activity as measured in the blood.

### Claim at position 25 (depends on 23)

23b. The method of claim 23a, wherein the soluble plasma factor is C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), interleukin-1 receptor antagonist (IL1Ra), hepatocyte growth factor (HGF), sCD163, osteopontin (OPN), or a combination thereof.

### Claim at position 26 (depends on 19)

23c. The method of claim 19, wherein the functional property is a nuclear factor- κB (NF-κB), and the contacting decreases the NF-κB activity as measured in the blood.

### Claim 24 (depends on 20, 21, 22, 23)

The method of any one of claims 20 to 23, wherein the subject has or is suspected of having a coronavirus infection.

### Claim 25 (depends on 24)

The method of claim 24, wherein the coronavirus is SARS-CoV, MERS-CoV, or SARS-CoV-2.

### Claim 26 (depends on 25)

The method of claim 25, wherein the coronavirus is SARS-CoV-2.

### Claim 27 (depends on 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 19 to 26, wherein chlorite is in the form of a pharmaceutically acceptable chlorite salt.

### Claim 28 (depends on 27)

The method of claim 27, wherein the chlorite salt is sodium chlorite.

### Claim 29 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 20 to 28, wherein the chlorite composition comprises a purified sodium chlorite, wherein the purified sodium chlorite is at least 98% pure.

### Claim 30 (depends on 29)

The method of claim 29, wherein the composition is in the form of a liquid further comprising a pH adjusting agent.

### Claim 31 (depends on 30)

The method of claim 30, wherein the pH adjusting agent is a phosphate buffer.

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 19 to 31, wherein the macrophage is in vitro.

### Claim 33 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 19 to 31, wherein the macrophage is in vivo.

### Claim 34 (depends on 33)

The method of claim 33, wherein the contacting comprises administering an effective amount of the chlorite composition to an individual.

### Claim 35 (depends on 34)

The method of claim 34, wherein the chlorite composition is administered intravenously.

### Claim 36 (depends on 33, 34, 35)

The method of any one of claims 33 to 35, wherein the individual has been diagnosed with COVID-19.

### Claim 37

A method of determining inhibition of an acute respiratory distress syndrome (ARDS)-induced macrophage activity by a chlorite agent, comprising:
contacting a macrophage of a subject having ARDS with a chlorite agent; and
assessing a level of one or more inflammatory factors selected from interleukin-18 (IL-18), C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), osteopontin (OPN), and interleukin-1 receptor antagonist (IL1Ra) after said contacting,
wherein a decrease in the level of the inflammatory factor after said contacting indicates that the chlorite agent is an inhibitor of the ARDS-induced macrophage activity.

### Claim 38 (depends on 37)

The method of claim 37, wherein the method further comprises:
measuring the level of the one or more inflammatory factors prior to said contacting.

### Claim 39 (depends on 37, 38)

The method of claim 37 or 38, wherein said assessing is at least one day after said contacting.

### Claim 40 (depends on 37, 38, 39)

The method of any one of claims 37 to 39, wherein the inflammatory factor is C-X-C motif chemokine ligand 9 (CXCL9).

### Claim 41 (depends on 37, 38, 39)

The method of any one of claims 37 to 39, wherein the inflammatory factor is interleukin-1 receptor antagonist (IL1Ra).

### Claim 42 (depends on 37, 38, 39)

The method of any one of claims 37 to 39, wherein the inflammatory factor is C-X-C motif chemokine ligand 10 (CXCL10).

### Claim 43 (depends on 37, 38, 39)

The method of any one of claims 37 to 39, wherein the inflammatory factor is osteopontin (OPN).
